{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T19:28:20Z","timestamp":1772393300905,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01HL128192"],"award-info":[{"award-number":["P01HL128192"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK 089507"],"award-info":[{"award-number":["P30 DK 089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002319"],"award-info":[{"award-number":["UL1 TR002319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR002548"],"award-info":[{"award-number":["UL1TR002548"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HAMBLE17K0"],"award-info":[{"award-number":["HAMBLE17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ZEMANI17K0"],"award-info":[{"award-number":["ZEMANI17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["ZEMANI17Y5"],"award-info":[{"award-number":["ZEMANI17Y5"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003542","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kunst Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T11:57:25Z","timestamp":1682337445000},"page":"652-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Willingness of people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-8164","authenticated-orcid":false,"given":"D.R.","family":"VanDevanter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-9337","authenticated-orcid":false,"given":"E.T.","family":"Zemanick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"M.W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-0644","authenticated-orcid":false,"given":"C.L.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2571","authenticated-orcid":false,"given":"K.","family":"Odem-Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Emerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.04.007_bib0001","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.007_bib0002","first-page":"192","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jcf.2023.04.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.02.012","article-title":"When triple therapy is not working: reverse iceberg perspective","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2023.04.007_bib0004","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.04.007_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26335","article-title":"How many billions is enough? Prioritizing profits over patients with cystic fibrosis","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.04.007_bib0006","doi-asserted-by":"crossref","unstructured":"Mayer-Hamblett N., Boyle M., VanDevanter D. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Thorax 2016 ;71(5):454\u2013461. May.","DOI":"10.1136\/thoraxjnl-2015-208123"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.007_bib0007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the CHEC-SC study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2023.04.007_bib0008","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.007_bib0009","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","article-title":"Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.007_bib0010","doi-asserted-by":"crossref","unstructured":"Clegg J.M., Malloy K.W., Brown R.F., Grisso A.G., Sokolow A.G. Ivacaftor withdrawal syndrome: a potentially life-threatening consequence from a life-saving medication. J Cyst Fibros 2022;21(3):549\u2013550. May.","DOI":"10.1016\/j.jcf.2021.07.021"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:32:29Z","timestamp":1751581949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199323000966"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Willingness of people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}